Physician profile
Vilayphonh Eure
NPI 1316999576
$12,907.57
in general payments reported to CMS, 2019-2025
46 companies · $657 in 2025
The $657 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,257 · 2022: $3,046 · 2023: $3,432 · 2024: $2,514 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,519 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,519.09 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,726.00 | 2021-2025 | |
| Novo Nordisk INC | $1,485.44 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Corcept Therapeutics | $1,277.58 | 2021-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $840.76 | 2021-2025 | Farxiga, Airsupra, Tagrisso |
| Amgen INC. | $780.30 | 2021-2025 | Otezla, Repatha, Evenity |
| Jazz Pharmaceuticals INC. | $701.20 | 2021-2025 | |
| Lilly USA, LLC | $700.61 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $614.57 | 2021-2025 | |
| Glaxosmithkline, LLC. | $513.95 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $382.92 | 2021-2023 | Xarelto |
| Pfizer INC. | $344.33 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.35 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $273.77 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $253.24 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $231.79 | 2021-2024 | Trintellix |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vilayphonh Eure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.